Vanda Pharmaceuticals (VNDA) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $4.05 +1.00%
EPS Growth %: -78.9%
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
UTMD, GCBC, ORPB, More
EPS Growth %: -78.9%
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
UTMD, GCBC, ORPB, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q1 EPS of ($0.17), $0.02 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $37.4 million versus the consensus estimate of $38.28 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- Greene County Bancorp (GCBC) Tops Q3 EPS by 73c
- Customers Bancorp (CUBI) Tops Q3 EPS by 11c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
